174 related articles for article (PubMed ID: 11408224)
1. Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes.
Sereno D; Holzmuller P; Mangot I; Cuny G; Ouaissi A; Lemesre JL
Antimicrob Agents Chemother; 2001 Jul; 45(7):2064-9. PubMed ID: 11408224
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of polyamine derivative compounds against Leishmania infantum promastigotes and axenic amastigotes.
Tavares J; Ouaissi A; Lin PK; Tomás A; Cordeiro-da-Silva A
Int J Parasitol; 2005 May; 35(6):637-46. PubMed ID: 15862577
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide-mediated proteasome-dependent oligonucleosomal DNA fragmentation in Leishmania amazonensis amastigotes.
Holzmuller P; Sereno D; Cavaleyra M; Mangot I; Daulouede S; Vincendeau P; Lemesre JL
Infect Immun; 2002 Jul; 70(7):3727-35. PubMed ID: 12065515
[TBL] [Abstract][Full Text] [Related]
4. A protein of the leucine-rich repeats (LRRs) superfamily is implicated in antimony resistance in Leishmania infantum amastigotes.
Genest PA; Haimeur A; Légaré D; Sereno D; Roy G; Messier N; Papadopoulou B; Ouellette M
Mol Biochem Parasitol; 2008 Mar; 158(1):95-9. PubMed ID: 18164495
[TBL] [Abstract][Full Text] [Related]
5. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action.
Sereno D; Cavaleyra M; Zemzoumi K; Maquaire S; Ouaissi A; Lemesre JL
Antimicrob Agents Chemother; 1998 Dec; 42(12):3097-102. PubMed ID: 9835497
[TBL] [Abstract][Full Text] [Related]
6. Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes.
El Fadili K; Messier N; Leprohon P; Roy G; Guimond C; Trudel N; Saravia NG; Papadopoulou B; Légaré D; Ouellette M
Antimicrob Agents Chemother; 2005 May; 49(5):1988-93. PubMed ID: 15855523
[TBL] [Abstract][Full Text] [Related]
7. Experimental studies on the evolution of antimony-resistant phenotype during the in vitro life cycle of Leishmania infantum: implications for the spread of chemoresistance in endemic areas.
Sereno D; Guilvard E; Maquaire S; Cavaleyra M; Holzmuller P; Ouaissi A; Lemesre JL
Acta Trop; 2001 Dec; 80(3):195-205. PubMed ID: 11700176
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of second line drugs on antimonyl-resistant amastigotes of Leishmania infantum.
Sereno D; Holzmuller P; Lemesre JL
Acta Trop; 2000 Jan; 74(1):25-31. PubMed ID: 10643904
[TBL] [Abstract][Full Text] [Related]
9. DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening.
Sereno D; Roy G; Lemesre JL; Papadopoulou B; Ouellette M
Antimicrob Agents Chemother; 2001 Apr; 45(4):1168-73. PubMed ID: 11257031
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of nicotinamide/antileishmanial drug combinations.
Gazanion E; Vergnes B; Seveno M; Garcia D; Oury B; Ait-Oudhia K; Ouaissi A; Sereno D
Parasitol Int; 2011 Jan; 60(1):19-24. PubMed ID: 20884376
[TBL] [Abstract][Full Text] [Related]
11. Stage-specific antileishmanial activity of an inhibitor of SIR2 histone deacetylase.
Vergnes B; Vanhille L; Ouaissi A; Sereno D
Acta Trop; 2005 May; 94(2):107-15. PubMed ID: 15860278
[TBL] [Abstract][Full Text] [Related]
12. Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity.
Borborema SE; Osso Junior JA; Andrade Junior HF; Nascimento Nd
Rev Soc Bras Med Trop; 2016 Apr; 49(2):196-203. PubMed ID: 27192589
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the anti-Leishmania effect induced by cisplatin, an anticancer drug.
Tavares J; Ouaissi M; Ouaissi A; Cordeiro-da-Silva A
Acta Trop; 2007 Aug; 103(2):133-41. PubMed ID: 17658446
[TBL] [Abstract][Full Text] [Related]
14. Comparative transcriptomic analysis of antimony resistant and susceptible Leishmania infantum lines.
Andrade JM; Gonçalves LO; Liarte DB; Lima DA; Guimarães FG; de Melo Resende D; Santi AMM; de Oliveira LM; Velloso JPL; Delfino RG; Pescher P; Späth GF; Ruiz JC; Murta SMF
Parasit Vectors; 2020 Nov; 13(1):600. PubMed ID: 33256787
[TBL] [Abstract][Full Text] [Related]
15. Antileishmanial effect of new indeno-1,5-naphthyridines, selective inhibitors of Leishmania infantum type IB DNA topoisomerase.
Tejería A; Pérez-Pertejo Y; Reguera RM; Balaña-Fouce R; Alonso C; Fuertes M; González M; Rubiales G; Palacios F
Eur J Med Chem; 2016 Nov; 124():740-749. PubMed ID: 27639365
[TBL] [Abstract][Full Text] [Related]
16. Down regulation of KMP-11 in Leishmania infantum axenic antimony resistant amastigotes as revealed by a proteomic screen.
El Fadili K; Drummelsmith J; Roy G; Jardim A; Ouellette M
Exp Parasitol; 2009 Sep; 123(1):51-7. PubMed ID: 19500579
[TBL] [Abstract][Full Text] [Related]
17. Leishmania infantum: stage-specific activity of pentavalent antimony related with the assay conditions.
Carrió J; de Colmenares M; Riera C; Gállego M; Arboix M; Portús M
Exp Parasitol; 2000 Jul; 95(3):209-14. PubMed ID: 10964649
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of Leishmania to novel pentavalent organometallics: Investigating impact on DNA and membrane integrity in antimony(III)-sensitive and -resistant strains.
Islam A; do Prado BR; Dittz D; Rodrigues BL; Silva SMD; do Monte-Neto RL; Shabeer M; Frézard F; Demicheli C
Drug Dev Res; 2024 May; 85(3):e22194. PubMed ID: 38704828
[TBL] [Abstract][Full Text] [Related]
19. Leishmania infantum amastigotes resistant to nitric oxide cytotoxicity: Impact on in vitro parasite developmental cycle and metabolic enzyme activities.
Holzmuller P; Hide M; Sereno D; Lemesre JL
Infect Genet Evol; 2006 May; 6(3):187-97. PubMed ID: 15905133
[TBL] [Abstract][Full Text] [Related]
20. MRPA-independent mechanisms of antimony resistance in Leishmania infantum.
Douanne N; Wagner V; Roy G; Leprohon P; Ouellette M; Fernandez-Prada C
Int J Parasitol Drugs Drug Resist; 2020 Aug; 13():28-37. PubMed ID: 32413766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
